News
ATTENTION NYSE: NVO INVESTORS: Contact Berger Montague About a Novo Nordisk A/S Class Action Lawsuit
Berger Montague PC is investigating claims under the federal securities laws against Novo Nordisk A/S (NYSE: NVO) ("Novo" or the "Company"), a global pharmaceutical company, headquartered in Denmark, ...
Texas Attorney General Ken Paxton is accusing Eli Lilly and Co. of a kickback scheme to induce medical providers to prescribe ...
The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern over the use of unapproved GLP-1 receptor agonists for weight loss, such as ...
Cambridge-based Biogen is looking to the growth of its Alzheimer’s drug Leqembi to offset the decline of its multiple ...
( NewsNation) — New research suggests popular weight loss drugs like Ozempic and Wegovy may affect more than just fat, ...
A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and ...
Novo Nordisk A/S (NYSE:NVO) is among the. Novo Nordisk A/S (NYSE:NVO) lowered its operating profit growth projections to ...
On this news, Novo Nordisk's stock price fell $15.06, or 21.8%, to close at $53.94 per share on July 2, 2025, thereby injuring investors. What Is The Lawsuit About?
If you’re pregnant or hoping to become pregnant, it’s natural to have questions about your medications. And if you’re taking ...
A wide variety of unapproved FDA drugs were discovered during inspections, including nearly 55,000 fake injectables and pills ...
Novo Nordisk's FY 2025 guidance cuts are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Click here to find out why I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results